Expert Interview
Looking at Vaxcyte's Phase 2 Topline Results for their VAX-24 Pneumococcal Conjugate Vaccine
Ticker(s): PCVX, MRK, PFEInstitution: Holy Name Medical Center
- Infectious disease consultant at a private practice
- Manages 10+ patients with pneumonia monthly
- Experience with Clinical research and specifically,immunomodulators for viral infections, vaccines, anti infectives
Roughly how many patients do you manage annually with invasive pneumococcal disease?
Added By: ben_adminWhich pneumococcal vaccines do you currently provide?
Added By: ben_adminWhat is your opinion on the data on VAX-24?
Added By: ben_adminHow does VAX-24 and VAX-31 compare to Prevnar-20?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
